問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Chi Mei Hospital, Liouying

Recruiting

List

139Cases

2025-11-01 - 2030-05-18

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-08-01 - 2028-03-31

Phase II

Active
A Phase II, Open-label, Single-arm Study of Osimertinib as Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Stage III, Unresectable Non-small Cell Lung Cancer (NEOLA)

  • Condition/Disease

    Lung Cancer

  • Test Drug

    錠劑

Participate Sites
7Sites

Recruiting7Sites

2021-06-01 - 2026-02-01

Phase I/II

Completed
A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients With Diffuse Large B-Cell Lymphoma Following First-Line Immunotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

  • Condition/Disease

    Diffuse Large B-cell Lymphoma

  • Test Drug

    injection injection Injection

Participate Sites
6Sites

Recruiting6Sites

2020-11-13 - 2026-12-31

Phase I

Active
A Phase I Study to Evaluate the Safety and Efficacy of RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer

  • Condition/Disease

    Pancreatic Cancer

  • Test Drug

    凍晶注射劑

Participate Sites
2Sites

Recruiting2Sites

2020-04-01 - 2028-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-12-01 - 2024-12-04

Phase III

Completed
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with a Safety and Dose Confirmation Run-in Period, to Evaluate the Efficacy and Safety of Obexelimab in Patients with Warm Autoimmune Hemolytic Anemia (SApHiAre)

  • Condition/Disease

    autoimmune hemolytic anemia, AIHA

  • Test Drug

    OBEXELIMAB (XmabR5871)

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2020-09-01 - 2026-12-31

Phase II

Active
A Multicenter, Open-label, Single-arm, Phase II Pan-Tumor Study in Patients Who Have Participated in Trials to Investigate Efficacy and Safety of ONO-4538 and Are Continuing ONO-4538 Treatment

  • Condition/Disease

    Pan-Tumor

  • Test Drug

    ONO-4538 (Nivolumab)

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting3Sites

Terminated3Sites

2015-11-30 - 2026-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2017-07-18 - 2026-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-10-01 - 2027-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting13Sites

Terminated3Sites

1 3 4 5 6 7 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB